This review outlines the advances and potential pitfalls of using high-sensitivity cardiac troponin assays for the early diagnosis of acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
High-sensitivity troponin assays may accelerate AMI diagnosis but risk overinterpretation; leaves open standardized protocols before routine adoption.
Although there is broad consensus that cardiac troponin I or T (cTn) is the preferred biomarker and complements clinical assessment and the 12-lead ECG in the early diagnosis of acute myocardial infarction, important uncertainties and questions remain on the value of high-sensitivity cTn assays, including their best clinical use. Although these assays have been introduced clinically in many countries, they still await regulatory approval in the USA. This review summarizes the recent advances and potential pitfalls in the clinical application of high-sensitivity cTn assays in the early diagnosis of acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Christian Mueller (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: